Here are the 424B prospectus supplements from Actuate Therapeutics, Inc. (ACTU) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ACTU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACTU filings page.
Actuate Therapeutics, Inc. (ACTU) is offering 30,985,900 common shares and 15,492,950 purchase warrants, plus 15,492,950 common shares issuable upon warrant exercise. Each two shares are sold with one warrant for a combined offering price of $0.71.
The warrants are immediately exercisable at $0.45 per share and expire five years after issuance. A 45-day underwriter option covers up to 4,647,885 additional shares and warrants to purchase 2,323,942 shares. The 4.99% beneficial-ownership limit may be increased to no more than 9.99%, effective on the 61st day after notice.
Estimated net proceeds, assuming no exercise of purchase warrants, are $9,961,479, or $11,495,978 if the underwriter fully exercises its option; proceeds are expected to fund working capital and general corporate purposes. ACTU believes net proceeds plus cash on hand as of October 26, 2026, are sufficient to fund its proposed operating plan for at least 12 months after that date. ACTU reports it does not meet Nasdaq Global Market’s $50 million minimum market value requirement and has until January 11, 2027, to regain compliance, requiring a market value of at least $50 million for 10 consecutive business days. The notice does not currently affect its Nasdaq listing.